Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is all part of the UNVC-Univec Conglomerate. Checkout the CEO Dr. David Dalton. Do you remember the video from Hope Global Conference when he said he was going to roll all of his companies into one company, Univec Conglomerate? (https://twitter.com/foxtrader22/status/1138419188698140672?s=21)
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
For more information contact:
Patrick Morris, Chief Executive Officer enermetalventures@gmail.com or 604-283-1722
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Neither the TSX Venture Exchange, nor the Canadian Securities Exchange, has in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.
Completion of the Transaction is subject to a number of conditions, including but not limited to, the consent of the TSX Venture Exchange to the delisting of the Company, the Canadian Securities Exchange having conditionally accepted the listing of the Company, and disinterested shareholder approval. The Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the terms and conditions of the proposed Transaction; and the proposed listing of the Company on the Canadian Securities Exchange. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward- looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that the Transaction will proceed on the terms contemplated above or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
$$$ UNVC $$$
This is all part of the UNVC-Univec Conglomerate. Checkout the CEO Dr. David Dalton. Do you remember the video from Hope Global Conference when he said he was going to roll all of his companies into one company, Univec Conglomerate? (https://twitter.com/foxtrader22/status/1138419188698140672?s=21)
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
For more information contact:
Patrick Morris, Chief Executive Officer enermetalventures@gmail.com or 604-283-1722
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Neither the TSX Venture Exchange, nor the Canadian Securities Exchange, has in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.
Completion of the Transaction is subject to a number of conditions, including but not limited to, the consent of the TSX Venture Exchange to the delisting of the Company, the Canadian Securities Exchange having conditionally accepted the listing of the Company, and disinterested shareholder approval. The Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the terms and conditions of the proposed Transaction; and the proposed listing of the Company on the Canadian Securities Exchange. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward- looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that the Transaction will proceed on the terms contemplated above or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
$$$ UNVC $$$
Univec Conglomerate Reinstated
https://twitter.com/xbudlightyrx/status/1138853031678750720?s=21
That is quite a list. Doc even discusses these accolades naming each at Hope Global Forum.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$
Univec Conglomerate has been reinstated with the Delaware Secretary of State.
Univec Conglomerate.
When you go to the Delaware SOS website input Univec Conglomerate and you will see the reinstatement of the largest Medical Marijuana conglomerate in the world:
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
$$$ UNVC $$$
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
I actually saw someone make reference to Solei too on the U.N.V.C board. That was a huge pps increase for Solei. I am sure the longs in this company are very happy and rich. I hope my investment does the same thing very soon:
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
Watch this again unvctrader.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton. This is a once in a lifetime opportunity:
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
$$$ UNVC $$$ Heading to a one company rollout into Univec. Hear it first hand from Univec CEO Dr. David Dalton.
$UNVC UNVC BOOM GO WATCH THE WHOLE THING THIS WILL GIVE U SOME INSIGHT pic.twitter.com/ysqnXcJlV5
— Deerhunter (@ball82811) June 11, 2019
That is very interesting Pete. Thank you.
$$$ UNVC $$$
$ UNVC $ Univec Conglomerate
https://www.cedar.com/CheckCode.do;jsessionid=0000ufvpRhlSBksSiOucOjEjx5y:188setvlh
FOR IMMEDIATE RELEASE
REWARDSTREAM SOLUTIONS INC. ANNOUNCES RESIGNATION AND APPOINTMENT OF DR. DAVID DALTON TO THE BOARD OF DIRECTORS AND GEOFF BALDERSON, AS CFO
VANCOUVER, BC, CANADA (APRIL 25th, 2019) – TSXV: REW (“Rewardstream”or the “Company”) is pleased to announce the appointment of Dr. David Dalton as a Director of the Company, replacing Danilen Villanuevae who has resigned as a director of the company. The company is also pleased to announce that Geoff Balderson has been appointed Chief Finacial Officer, replacing Usama Chaudhry.
Currently Dr. Dalton is a director of
“David’s impressive background will provide our Board with a wealth of experience and skills,” said Patrick Morris. “We are looking forward to his valuable contributions on a variety of significant issues on growing our business.”
In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom.
Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
RewardStreams board of directors now consists of 3 members, Patrick Morris, Geoff Balderson and Dr. David Dalton.
About Rewardstream Solutions Inc.
Rewardstream is a listed company on the TSX.V
For more information contact:
On behalf of the Board of Directors Patrick Morris, CEO pm@primarycobalt.com 604-283-1722 Forward-Looking Information
This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.
Neither the Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth
of Pennsylvania to grow and process medical cannabis.
$$ UNVC $$Univec Conglomerate
https://www.cedar.com/CheckCode.do;jsessionid=0000ufvpRhlSBksSiOucOjEjx5y:188setvlh
FOR IMMEDIATE RELEASE
REWARDSTREAM SOLUTIONS INC. ANNOUNCES RESIGNATION AND APPOINTMENT OF DR. DAVID DALTON TO THE BOARD OF DIRECTORS AND GEOFF BALDERSON, AS CFO
VANCOUVER, BC, CANADA (APRIL 25th, 2019) – TSXV: REW (“Rewardstream”or the “Company”) is pleased to announce the appointment of Dr. David Dalton as a Director of the Company, replacing Danilen Villanuevae who has resigned as a director of the company. The company is also pleased to announce that Geoff Balderson has been appointed Chief Finacial Officer, replacing Usama Chaudhry.
Currently Dr. Dalton is a director of
“David’s impressive background will provide our Board with a wealth of experience and skills,” said Patrick Morris. “We are looking forward to his valuable contributions on a variety of significant issues on growing our business.”
In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom.
Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
RewardStreams board of directors now consists of 3 members, Patrick Morris, Geoff Balderson and Dr. David Dalton.
About Rewardstream Solutions Inc.
Rewardstream is a listed company on the TSX.V
For more information contact:
On behalf of the Board of Directors Patrick Morris, CEO pm@primarycobalt.com 604-283-1722 Forward-Looking Information
This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.
Neither the Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth
of Pennsylvania to grow and process medical cannabis.
$$$ UNVC $$$ Univec Conglomerate
https://www.cedar.com/CheckCode.do;jsessionid=0000ufvpRhlSBksSiOucOjEjx5y:188setvlh
FOR IMMEDIATE RELEASE
REWARDSTREAM SOLUTIONS INC. ANNOUNCES RESIGNATION AND APPOINTMENT OF DR. DAVID DALTON TO THE BOARD OF DIRECTORS AND GEOFF BALDERSON, AS CFO
VANCOUVER, BC, CANADA (APRIL 25th, 2019) – TSXV: REW (“Rewardstream”or the “Company”) is pleased to announce the appointment of Dr. David Dalton as a Director of the Company, replacing Danilen Villanuevae who has resigned as a director of the company. The company is also pleased to announce that Geoff Balderson has been appointed Chief Finacial Officer, replacing Usama Chaudhry.
Currently Dr. Dalton is a director of
“David’s impressive background will provide our Board with a wealth of experience and skills,” said Patrick Morris. “We are looking forward to his valuable contributions on a variety of significant issues on growing our business.”
In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom.
Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
RewardStreams board of directors now consists of 3 members, Patrick Morris, Geoff Balderson and Dr. David Dalton.
About Rewardstream Solutions Inc.
Rewardstream is a listed company on the TSX.V
For more information contact:
On behalf of the Board of Directors Patrick Morris, CEO pm@primarycobalt.com 604-283-1722 Forward-Looking Information
This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.
Neither the Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth
of Pennsylvania to grow and process medical cannabis.
$$$ UNVC $$$
Thank you to MikeyT on UNVC board for providing this video from Hope Global Forums recently. UNVC is going to be a major global medical cannabis and cbd powerhouse.
“At Hope Global Forums Dr Dalton talks about being headed for a ONE company rollup! HRI, PPSI, WELLNESS TELADOC, UNIVEC, WELLNESS RX (CARF ACCREDITED) AND UNIVEC CONGLOMERATE INC ALL BECOMING ONE!!
Click on YOUTUBE LINK. Listen to video, Doc speaks from about 3:50 mark and then later from the 36:45 minute mark. Plan is laid out on the table:”
$$$ UNVC $$$
Univec Conglomerate has been reinstated with the Delaware Secretary of State.
Univec Conglomerate.
When you go to the Delaware SOS website input Univec Conglomerate and you will see the reinstatement of the largest Medical Marijuana conglomerate in the world:
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
$$$ UNVC $$$
$$$ UNVC $$$
Wellness Teladoc and HUD
Target Asthma and Addiction
https://www.linkedin.com/feed/update/urn:li:activity:6543929699041632257
Wellness Teladoc is a UNVC subsidiary.
$$$ UNVC $$$
UmbBiopark
Paragon success 1.2 Billion
Jay Perman University of Maryland President
Connect the dot
https://www.linkedin.com/feed/update/urn:li:activity:6544211521503850496
$$$UNVC-Univec Conglomerate $$$
is making big moves to be a Global medical marijuana giant.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
$$$ UNVC $$$
$$$ UNVC $$$
https://twitter.com/xbudlightyrx/status/1138415886967197699?s=21
$UNVC Dalton is receiving an award for being one for the Top 100 Healthcare Leaders of the WORLD!! And speaking! June 20th
After being a long for almost two years, I can’t tell you how excited I am for us as shareholders. UNVC is going to be a life changer. Go ahead and listen to the video of Dr. Dalton at the Hope Global Forum speak about Univec Conglomerate.
$$$ UNVC $$$
Univec Conglomerate has been reinstated with the Delaware Secretary of State.
Univec Conglomerate.
When you go to the Delaware SOS website input Univec Conglomerate and you will see the reinstatement of the largest Medical Marijuana conglomerate in the world:
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
$$$ UNVC $$$
Replies:
$UNVC Yes sir the pedigree of Dr.David Dalton
wrenchman on 6/7/2019 7:41:01 AM
Report TOS
$$$UNVC-Univec Conglomerate $$$
is making big moves to be a Global medical marijuana giant.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
$$$ UNVC $$$
I agree. The float has to be super small with the way the price per share moves quickly on thin air.
$$$ UNVC $$$
I like the fact that we are seeing more activity on the surface as of recently by Dr. Dalton. He is doing a great job of posting more on linkedin, we saw the Univec Conglomerate reinstatement on the Delaware SOS, we got the pr on Reward Stream naming him as Director/Chairman/CEO, we got the youtube video of him speaking at Hope Global Forum which confirms the great dd by the Circle. The price per share along with the trading volume shows that the market likes this activity in a very positive way. Keep it up Dr. Dalton.
$$$ UNVC $$$
Yes KW. The IFA event coming up on 6/20/19 could also serve as a catalyst.
https://www.linkedin.com/feed/update/urn:li:activity:6531702534363496448
“Top 100 Healthcare Leaders across the world.We will make a change for poor and indigent and create wealth for middle class. It takes a plan then you work your plan.” - Dalton
$$$ UNVC $$$
Only Dr. Dalton knows when.
$$$ UNVC $$$
UNVC is going to be a major medical marijuana global powerhouse.
$$$ UNVC $$$
Thank you to MikeyT on UNVC board for providing this video from Hope Global Forums recently. You are going to want to see Dr. Dalton speak at the 3:50 mark. CEO Dalton talks about rolling multiple companies into UNVC.
“At Hope Global Forums Dr Dalton talks about being headed for a ONE company rollup! HRI, PPSI, WELLNESS TELADOC, UNIVEC, WELLNESS RX (CARF ACCREDITED) AND UNIVEC CONGLOMERATE INC ALL BECOMING ONE!!
Click on YOUTUBE LINK. Listen to video, Doc speaks from about 3:50 mark and then later from the 36:45 minute mark. Plan is laid out on the table:”
Thank you to MikeyT on UNVC board for providing this video from Hope Global Forums recently. You are going to want to see Dr. Dalton speak at the 3:50 mark:
“At Hope Global Forums Dr Dalton talks about being headed for a ONE company rollup! HRI, PPSI, WELLNESS TELADOC, UNIVEC, WELLNESS RX (CARF ACCREDITED) AND UNIVEC CONGLOMERATE INC ALL BECOMING ONE!!
Click on YOUTUBE LINK. Listen to video, Doc speaks from about 3:50 mark and then later from the 36:45 minute mark. Plan is laid out on the table:”
Thank you to MikeyT on UNVC board for providing this video from Hope Global Forums recently:
“At Hope Global Forums Dr Dalton talks about being headed for a ONE company rollup! HRI, PPSI, WELLNESS TELADOC, UNIVEC, WELLNESS RX (CARF ACCREDITED) AND UNIVEC CONGLOMERATE INC ALL BECOMING ONE!!
Click on YOUTUBE LINK. Listen to video, Doc speaks from about 3:50 mark and then later from the 36:45 minute mark. Plan is laid out on the table:”
Wow!!!!! He refers to Univec as a penny stock that will allow small time investors to create wealth.
$$$ UNVC $$$
I am confident that we will. UNVC has the most verifiable dd out there in otc Pinkeyland. Cross check Dr. David Dalton who is the CEO and you will agree. Don’t take my word for it. Once you research Univec Conglomerate and what they have going on, you will be very comfortable. GLTA.
$$$ UNVC $$$
I had to re-post this for new investors. This is unbelievable to me. Wow! We are actually investors of this medical marijuana powerhouse.
$$$ UNVC $$$ Univec Conglomerate
Univec Conglomerate has been reinstated with the Delaware Secretary of State.
Univec Conglomerate.
When you go to the Delaware SOS website input Univec Conglomerate and you will see the reinstatement of the largest Medical Marijuana conglomerate in the world:
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
$$$ UNVC $$$
$$$ UNVC $$$ Univec Conglomerate
Univec Conglomerate has been reinstated with the Delaware Secretary of State.
Univec Conglomerate.
When you go to the Delaware SOS website input Univec Conglomerate and you will see the reinstatement of the largest Medical Marijuana conglomerate in the world:
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
$$$ UNVC $$$
$$$ UNVC $$$
This is all part of the Univec Conglomerate plan:
$$$ UNVC $$$ David Dalton
https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23868510
RewardStream Solutions Inc. Key Developments
RewardStream Solutions Inc. Announces Management Changes
Apr 26 19
RewardStream Solutions Inc. announced the appointment of Dr. David Dalton as a Director of the company, replacing Danilen Villanuevae who has resigned as a director of the company. The company is also announced that Geoff Balderson has been appointed Chief Financial Officer, replacing Usama Chaudhry. Currently Dr. Dalton is a director of AGRIMED. In addition to over 45 years' experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc. and Univec Inc. (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom.
https://www.prweb.com/releases/univec_conglomerate_inc_adds_past_vice_president_of_merck_to_board_of_directors/prweb16354825.htm
UNIVEC CONGLOMERATE INC. Adds Past Vice President of Merck to Board of Directors
Share Article
JOHN C. PEOPLES past vice president of Merck joins the Board of Directors of Univec Conglomerate Inc.
OWINGS MILLS, MD. (PRWEB) JUNE 06, 2019
John C. Peoples, Past Vice President of Merck joins the Board of Directors of Univec Conglomerate Inc. bringing demonstrated professional skills in marketing management.
Univec Conglomerate Inc. is a specialty pharmaceutical and cannabis company that has focus on medication for pain and addiction treatment through transdermal delivery.
$$$ UNVC $$$